



Spectrum Pharmaceuticals, Inc.  
Investor Relations Department  
157 Technology Drive  
Irvine, CA 92618  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

#### NASDAQ: SPPI <sup>1</sup>

|                   |                            |
|-------------------|----------------------------|
| Last Trade:       | 9.84                       |
| Trade Time:       | 4:00 PM ET<br>Sep 25, 2017 |
| Change:           | 0.39  (4.127%)             |
| Day Range         | 9.55 - 9.93                |
| 52-Week Range     | 3.21 - 10.77               |
| Volume            | 1,093,100                  |
| Market Cap. (\$M) | 831.480                    |
| Shares Out (M)    | 84.500                     |

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Spectrum Pharmaceuticals is a leading biotechnology company with a focus in Oncology and Hematology. The Company's strategy is comprised of acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products; establishing a commercial organization for its approved drugs; continuing to build a team with people who have demonstrated skills, passion, commitment and have a track record of success in its areas of focus; and, leveraging the expertise of partners around the world to assist it in the execution of its strategy.

Spectrum Pharmaceuticals' stock is traded through the Nasdaq Global Market System.

Ticker Symbol: [SPPI](#)

... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

- Sep 5, 2017*  
[Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September](#)
- Aug 17, 2017*  
[Spectrum Pharmaceuticals to Present Corporate Update at the 2017 Southern California Investor Conference in Newport Beach on Thursday, August 24th](#)
- Aug 14, 2017*  
[Spectrum Pharmaceuticals Announces Initiation of the Registrational Phase 3 Trial of Qapzola™ \(apaziquone\) in Patients with Non-Muscle Invasive Bladder Cancer \(NMIBC\)](#)
- Aug 3, 2017*  
[Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Pipeline Update](#)
- Aug 1, 2017*  
[Spectrum Pharmaceuticals Announces Completion of Enrollment in the Phase 3 Pivotal Study \(ADVANCE\) of ROLONTIS™ \(eflapegrastim\), a Novel Long-Acting GCSF](#)

### Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

### Financials [\[ View all \]](#)

#### [Second Quarter Financial Results](#)

- Mar 14, 2017*  
[Annual Report \(10-K\)](#)
- Apr 17, 2017*  
[Definitive Proxy Statement](#)
- Aug 4, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 4, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 14, 2016*  
[Quarterly Report \(10-Q\)](#)